Using cardiac magnetic resonance imaging to detect early changes in heart muscle that may help predict patients who are at risk of developing toxicity from anthracycline chemotherapy.

Use of myocardial tissue characterization by cardiac magnetic resonance imaging to predict left ventricular dysfunction in patients undergoing anthracycline chemotherapy.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12612001100886

Enrollment

Registered

2012-10-16

Start date

2012-10-12

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Aim is to assess whether a novel cardiac magnetic resonance imaging (CMR) technique, T2 mapping, can identify myocardial edema as a marker of myocardial injury and be used as a predictor of cardiac dysfunction in patients undergoing anthracycline chemotherapy.

Interventions

Magnetic resonance imaging scan of the heart (60 minutes duration) before chemotherapy, on completion of chemotherapy cycles (~3 months) and at 1 year after commencement of chemotherapy.We will use novel MRI sequences (T1 and T2 mapping) which aim to quantify specific magnetic properties of the heart muscle that related to myocardial edema (seen in inflammation) and fibrosis.

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

Patient referred for anthracycline chemotherapy (i.e. for lymphoma) Healthy controls

Exclusion criteria

1. Acute renal failure or chronic renal failure manifest by GFR<60 ml/kg/1.73m2. 2. Contraindication to MRI scanning. 3. Known hypersensitivity to gadolinium. 4. Atrial fibrillation at baseline. 5. Pregnancy.

Outcome results